{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:11:22Z","timestamp":1785730282395,"version":"3.56.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,31]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>BAY 1143572, a novel and selective P-TEFb\/CDK9 inhibitor, possessed significant antitumor activity against primary ATL cells in vitro. BAY 1143572 possessed significant antitumor activity in an ATL mouse model based on tumor cells from a patient.<\/jats:p>","DOI":"10.1182\/blood-2016-09-741983","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T20:40:18Z","timestamp":1498250418000},"page":"1114-1124","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma"],"prefix":"10.1182","volume":"130","author":[{"given":"Tomoko","family":"Narita","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-0777","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Tumor Immunology, School of Medicine, Aichi Medical University, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Takino","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetsu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Scholz","sequence":"additional","affiliation":[{"name":"Bayer AG Pharmaceuticals Division, Berlin, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lienau","sequence":"additional","affiliation":[{"name":"Bayer AG Pharmaceuticals Division, Berlin, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taruho","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Bayer Yakuhin, Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Tumor Immunology, School of Medicine, Aichi Medical University, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111904370587000_B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"10","key":"2019111904370587000_B2","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","article-title":"Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera","volume":"78","author":"Hinuma","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2019111904370587000_B3","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111904370587000_B4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111904370587000_B5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-011-0941-5","article-title":"Antibody therapy for adult T-cell leukemia-lymphoma","volume":"94","author":"Ishida","year":"2011","journal-title":"Int J Hematol"},{"issue":"3","key":"2019111904370587000_B6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111904370587000_B7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111904370587000_B8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111904370587000_B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"34","key":"2019111904370587000_B10","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult t-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111904370587000_B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","article-title":"Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111904370587000_B12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin Immunol"},{"issue":"5","key":"2019111904370587000_B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc3496","article-title":"Dysregulation of the basal RNA polymerase transcription apparatus in cancer","volume":"13","author":"Bywater","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019111904370587000_B14","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"18","key":"2019111904370587000_B15","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111904370587000_B16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/path.1588","article-title":"CDK9\/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation","volume":"203","author":"Bellan","year":"2004","journal-title":"J Pathol"},{"issue":"3","key":"2019111904370587000_B17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/cbt.4.3.1497","article-title":"Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors","volume":"4","author":"De Falco","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2019111904370587000_B18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/sj.cdd.4402008","article-title":"Abrogation of signal-dependent activation of the cdk9\/cyclin T2a complex in human RD rhabdomyosarcoma cells","volume":"14","author":"Simone","year":"2007","journal-title":"Cell Death Differ"},{"issue":"13","key":"2019111904370587000_B19","doi-asserted-by":"crossref","first-page":"9978","DOI":"10.1074\/jbc.M002285200","article-title":"Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation","volume":"276","author":"Lee","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111904370587000_B20","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1128\/JVI.80.10.4781-4791.2006","article-title":"Tax interacts with P-TEFb in a novel manner to stimulate human T-lymphotropic virus type 1 transcription","volume":"80","author":"Zhou","year":"2006","journal-title":"J Virol"},{"issue":"20","key":"2019111904370587000_B21","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.1128\/JVI.00408-07","article-title":"Modulation of the Brd4\/P-TEFb interaction by the human T-lymphotropic virus type 1 tax protein","volume":"81","author":"Cho","year":"2007","journal-title":"J Virol"},{"key":"2019111904370587000_B22","volume-title":"Cancer Res","author":"Scholz","year":"2015"},{"issue":"10 Pt 1","key":"2019111904370587000_B23","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111904370587000_B24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/j.1349-7006.2012.02371.x","article-title":"Tax is a potential molecular target for immunotherapy of adult T-cell leukemia\/lymphoma","volume":"103","author":"Suzuki","year":"2012","journal-title":"Cancer Sci"},{"issue":"4586","key":"2019111904370587000_B25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.6600519","article-title":"Isolation and transmission of human retrovirus (human t-cell leukemia virus)","volume":"219","author":"Popovic","year":"1983","journal-title":"Science"},{"issue":"9","key":"2019111904370587000_B26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1349-7006.1996.tb02116.x","article-title":"Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice","volume":"87","author":"Imada","year":"1996","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"2019111904370587000_B27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1349-7006.2004.tb03224.x","article-title":"Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo","volume":"95","author":"Koga","year":"2004","journal-title":"Cancer Sci"},{"issue":"6","key":"2019111904370587000_B28","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","article-title":"Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma","volume":"64","author":"Niwa","year":"2004","journal-title":"Cancer Res"},{"issue":"22","key":"2019111904370587000_B29","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111904370587000_B30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4049\/jimmunol.1301952","article-title":"HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia\/lymphoma patients after allogeneic hematopoietic stem cell transplantation","volume":"192","author":"Narita","year":"2014","journal-title":"J Immunol"},{"issue":"2","key":"2019111904370587000_B31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2008.01038.x","article-title":"Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1","volume":"100","author":"Ri","year":"2009","journal-title":"Cancer Sci"},{"issue":"1","key":"2019111904370587000_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1620\/tjem.157.1","article-title":"Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I","volume":"157","author":"Lee","year":"1989","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"2019111904370587000_B33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12231","article-title":"Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia\/lymphoma mouse model","volume":"92","author":"Mori","year":"2014","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111904370587000_B34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1349-7006.1988.tb00028.x","article-title":"Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia\/lymphoma virus type-I seropositive healthy carriers","volume":"79","author":"Motoi","year":"1988","journal-title":"Jpn J Cancer Res"},{"issue":"11","key":"2019111904370587000_B35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3324\/haematol.2012.062539","article-title":"Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"97","author":"Karp","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"2019111904370587000_B36","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-11-3203","article-title":"The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial","volume":"18","author":"Luke","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111904370587000_B37","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1158\/1078-0432.CCR-14-0805","article-title":"Phase I trial of bortezomib (PS-341; NSC 681239) and \u201cnonhybrid\u201d (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms","volume":"20","author":"Holkova","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111904370587000_B38","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2010-09-310862","article-title":"Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias","volume":"117","author":"Karp","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111904370587000_B39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"2019111904370587000_B40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J Transl Med"},{"issue":"18","key":"2019111904370587000_B41","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"2019111904370587000_B42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br J Cancer"},{"issue":"18","key":"2019111904370587000_B43","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-14-0325","article-title":"Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors","volume":"20","author":"van der Biessen","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111904370587000_B44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2019111904370587000_B45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/15384101.2016.1138186","article-title":"Overview of CDK9 as a target in cancer research","volume":"15","author":"Morales","year":"2016","journal-title":"Cell Cycle"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/9\/1114\/1405260\/blood741983.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/9\/1114\/1405260\/blood741983.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:37:42Z","timestamp":1574138262000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/9\/1114\/37003\/Cyclindependent-kinase-9-is-a-novel-specific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,8,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-741983","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}